Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
R&D Pipeline
3 min read
An Overview of Vertex Pharmaceuticals's 97 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
27 July 2023
Vertex Pharmaceuticals, Inc. is a biopharmaceutical company that was founded in 1989 and is headquartered in Massachusetts, United States.
Advanced Tech.
5 min read
Targeting the Autophagy Pathway as a Potential Novel Therapy for FXS and ASD
27 July 2023
A recent study has found that elevated levels of the protein MAP1B result in neuronal autophagy defects closely linked to human ASD. Treating FXS and ASD with rapamycin, a drug that inhibits autophagy, may be a promising potential therapy.
R&D Pipeline
3 min read
An Overview of Otsuka Holdings's 313 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
27 July 2023
Otsuka Holdings Co., Ltd. is a pharmaceutical organization based in Tokyo-to, Japan. It was founded in 1921 and has since become a prominent player in the biomedicine industry.
Advanced Tech.
5 min read
Sequence-based drug design with AI: A Paradigm Shift in Drug Discovery
26 July 2023
These limitations include the absence of high-resolution structures for numerous proteins, the challenge of accurately predicting active sites, defining binding pockets for novel targets with multiple domains, and anticipating allosteric sites.
R&D Pipeline
2 min read
An Overview of Daiichi Sankyo 's 395 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
26 July 2023
Daiichi Sankyo Co., Ltd. is a pharmaceutical organization founded in 2005 and based in Tokyo, Japan. The company operates in the field of biomedicine and has a diverse portfolio of drugs targeting various therapeutic areas.
Latest Hotspot
2 min read
CanSino's Herpes Zoster vaccine CS-2032 has been approved for clinical use in Canada
26 July 2023
On July 23, CanSino Biologics announced that its recombinant shingles vaccine CS-2032, developed in collaboration with Vaccitech, has received clinical trial approval from Health Canada.
R&D Pipeline
3 min read
An Overview of UCB's 147 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
26 July 2023
UCB SA is a pharmaceutical organization that was founded in 1928 and is located in Brussels Hoofdstedelijk Gewest, Belgium.
Drug Insights
3 min read
Ritlecitinib - Dual Inhibitor of JAK3/TEC
26 July 2023
Ritlecitinib, trade name LITFULO, is a small molecule drug targeting JAK3 and TEC (see Figure 2-9 for molecular structure).
Latest Hotspot
3 min read
Roche introduces Alnylam's hypertension RNAi therapy, Zilebesiran, with a potential transaction value of up to 2.8 billion dollars
26 July 2023
On July 24, 2023, Alnylam announced that it has reached a strategic agreement with Roche to develop and commercialize Zilebesiran, Alnylam's RNAi therapeutic drug for the treatment of hypertension.
R&D Pipeline
2 min read
An Overview of Organon 's 125 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
26 July 2023
Organon & Co. is a pharmaceutical organization founded in 2020 and based in Noord-Brabant, Netherlands. The company operates in the field of biomedicine and focuses on the development of drugs for various therapeutic areas.
R&D Pipeline
3 min read
An Overview of Jiangsu Hengrui's 257 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
26 July 2023
Jiangsu Hengrui Pharmaceutical Group Co. Ltd. is a pharmaceutical organization based in Jiangsu Sheng, China. It was founded in 1996 and has since become a prominent player in the biomedicine field.
Drug Insights
2 min read
Anaprazole Sodium——Next Generation Proton Pump Inhibitors
26 July 2023
Anaprazole Sodium is a small molecule proton pump inhibitor (PPI) developed by Beijing Sihuan Pharmaceutical Co. Ltd., approved by NMPA on June 21, 2023, for the treatment of duodenal ulcers.